Literature DB >> 25857751

Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and β-klotho expression decrease with fasting in northern elephant seals.

Miwa Suzuki1, Andrew Y Lee2, José Pablo Vázquez-Medina2, Jose A Viscarra2, Daniel E Crocker3, Rudy M Ortiz2.   

Abstract

Fibroblast growth factor (FGF)-21 is secreted from the liver, pancreas, and adipose in response to prolonged fasting/starvation to facilitate lipid and glucose metabolism. Northern elephant seals naturally fast for several months, maintaining a relatively elevated metabolic rate to satisfy their energetic requirements. Thus, to better understand the impact of prolonged food deprivation on FGF21-associated changes, we analyzed the expression of FGF21, FGF receptor-1 (FGFR1), β-klotho (KLB; a co-activator of FGFR) in adipose, and plasma FGF21, glucose and 3-hydroxybutyrate in fasted elephant seal pups. Expression of FGFR1 and KLB mRNA decreased 98% and 43%, respectively, with fasting duration. While the 80% decrease in mean adipose FGF21 mRNA expression with fasting did not reach statistical significance, it paralleled the 39% decrease in plasma FGF21 concentrations suggesting that FGF21 is suppressed with fasting in elephant seals. Data demonstrate an atypical response of FGF21 to prolonged fasting in a mammal suggesting that FGF21-mediated mechanisms have evolved differentially in elephant seals. Furthermore, the typical fasting-induced, FGF21-mediated actions such as the inhibition of lipolysis in adipose may not be required in elephant seals as part of a naturally adapted mechanism to support their unique metabolic demands during prolonged fasting.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elephant seal; Fasting; Fibroblast growth factor 21; Food deprivation

Mesh:

Substances:

Year:  2015        PMID: 25857751      PMCID: PMC4457680          DOI: 10.1016/j.ygcen.2015.03.009

Source DB:  PubMed          Journal:  Gen Comp Endocrinol        ISSN: 0016-6480            Impact factor:   2.822


  27 in total

1.  TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway.

Authors:  Julieta Díaz-Delfín; Elayne Hondares; Roser Iglesias; Marta Giralt; Carme Caelles; Francesc Villarroya
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

2.  The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue.

Authors:  Andrew C Adams; Chaofeng Yang; Tamer Coskun; Christine C Cheng; Ruth E Gimeno; Yongde Luo; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2012-08-28       Impact factor: 7.422

3.  Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation.

Authors:  Peter Plomgaard; Karim Bouzakri; Rikke Krogh-Madsen; Bettina Mittendorfer; Juleen R Zierath; Bente K Pedersen
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

4.  Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.

Authors:  Julie S Moyers; Tatiyana L Shiyanova; Farrokh Mehrbod; James D Dunbar; Timothy W Noblitt; Keith A Otto; Anne Reifel-Miller; Alexei Kharitonenkov
Journal:  J Cell Physiol       Date:  2007-01       Impact factor: 6.384

5.  Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes.

Authors:  Hong Wang; Li Qiang; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

6.  The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

Authors:  Cecilia Gälman; Tomas Lundåsen; Alexei Kharitonenkov; Holly A Bina; Mats Eriksson; Ingiäld Hafström; Maria Dahlin; Per Amark; Bo Angelin; Mats Rudling
Journal:  Cell Metab       Date:  2008-08       Impact factor: 27.287

7.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.

Authors:  Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

8.  Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver.

Authors:  Yuhei Hotta; Hirotoshi Nakamura; Morichika Konishi; Yusuke Murata; Hiroyuki Takagi; Shigenobu Matsumura; Kazuo Inoue; Tohru Fushiki; Nobuyuki Itoh
Journal:  Endocrinology       Date:  2009-07-09       Impact factor: 4.736

9.  betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c.

Authors:  Masashi Suzuki; Yuriko Uehara; Kaori Motomura-Matsuzaka; Junko Oki; Yoshinori Koyama; Miho Kimura; Masahiro Asada; Akiko Komi-Kuramochi; Syuichi Oka; Toru Imamura
Journal:  Mol Endocrinol       Date:  2008-01-10

10.  Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man.

Authors:  K Y Ho; J D Veldhuis; M L Johnson; R Furlanetto; W S Evans; K G Alberti; M O Thorner
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

View more
  2 in total

1.  Feeding a Modified Fish Diet to Bottlenose Dolphins Leads to an Increase in Serum Adiponectin and Sphingolipids.

Authors:  Philip M Sobolesky; Tyler S Harrell; Celeste Parry; Stephanie Venn-Watson; Michael G Janech
Journal:  Front Endocrinol (Lausanne)       Date:  2016-04-21       Impact factor: 5.555

2.  Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease.

Authors:  Wei Zhao; Asif Rasheed; Emmi Tikkanen; Jung-Jin Lee; Adam S Butterworth; Joanna M M Howson; Themistocles L Assimes; Rajiv Chowdhury; Marju Orho-Melander; Scott Damrauer; Aeron Small; Senay Asma; Minako Imamura; Toshimasa Yamauch; John C Chambers; Peng Chen; Bishwa R Sapkota; Nabi Shah; Sehrish Jabeen; Praveen Surendran; Yingchang Lu; Weihua Zhang; Atif Imran; Shahid Abbas; Faisal Majeed; Kevin Trindade; Nadeem Qamar; Nadeem Hayyat Mallick; Zia Yaqoob; Tahir Saghir; Syed Nadeem Hasan Rizvi; Anis Memon; Syed Zahed Rasheed; Fazal-Ur-Rehman Memon; Khalid Mehmood; Naveeduddin Ahmed; Irshad Hussain Qureshi; Wasim Iqbal; Uzma Malik; Narinder Mehra; Jane Z Kuo; Wayne H-H Sheu; Xiuqing Guo; Chao A Hsiung; Jyh-Ming J Juang; Kent D Taylor; Yi-Jen Hung; Wen-Jane Lee; Thomas Quertermous; I-Te Lee; Chih-Cheng Hsu; Erwin P Bottinger; Sarju Ralhan; Yik Ying Teo; Tzung-Dau Wang; Dewan S Alam; Emanuele Di Angelantonio; Steve Epstein; Sune F Nielsen; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Robin Young; Marianne Benn; Ruth Frikke-Schmidt; Pia R Kamstrup; J Wouter Jukema; Naveed Sattar; Roelof Smit; Ren-Hua Chung; Kae-Woei Liang; Sonia Anand; Dharambir K Sanghera; Samuli Ripatti; Ruth J F Loos; Jaspal S Kooner; E Shyong Tai; Jerome I Rotter; Yii-Der Ida Chen; Philippe Frossard; Shiro Maeda; Takashi Kadowaki; Muredach Reilly; Guillaume Pare; Olle Melander; Veikko Salomaa; Daniel J Rader; John Danesh; Benjamin F Voight; Danish Saleheen
Journal:  Nat Genet       Date:  2017-09-04       Impact factor: 38.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.